The long-term goals ofthe Hematopoietic Development &Malignancy Program (HDMP) are to elucidate basic mechanisms regulating normal and malignant hematopoiesis and to use this information to develop strategies for the prevention, diagnosis, prognostic stratification, and treatment of hematopoietic malignancies. We have identified areas of institutional strength and developed the following specific translational goals of the HDMP: 1) to leverage local expertise in cancer genomics to identify novel recurrent mutations in hematopoietic malignancies and develop their translational potential;2) to expand translational research in multiple myeloma and lymphoma;3) to take advantage of local expertise in fundamental hematopoiesis research to expand translational research in bone marrow failure syndromes;4) to utilize local expertise in fundamental immunology and stem cell biology research to expand translational research in stem cell transplantation. Working groups in leukemia, lymphoma &myeloma, bone marrow failure and transplantation biology have been established to develop, review, prioritize and conduct translational research. The HDMP will foster collaborative translational research and provide training of junior investigators through research seminars, journal clubs, work-in-progress meetings and the annual HDMP retreat. The HDMP has 29 members from four Departments and one School. The HDMP is supported by $11,684,316 in funding, of which $4,798,898 is NCI funding and $6,264,597 is other peer reviewed funding. In the last grant period, members ofthe HDMP published 260 manuscripts, of which 34.6% represent interprogrammatic and 13.1% resulted from intra-programmatic collaborations.
The goal of the Hematopoietic Development &Malignancy Program is to improve the diagnosis and treatment of blood cancers, including leukemia, multiple myeloma, and lymphoma through clinical application of advances in basic research.
|Johnson, Kimberly J; Zoellner, Nancy L; Gutmann, David H (2016) Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol 42:53-9|
|Zuiani, Adam; Chen, Kevin; Schwarz, Megan C et al. (2016) A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. J Virol 90:10499-10512|
|Abboud, Ramzi; Keller, Jesse; Slade, Michael et al. (2016) Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. Biol Blood Marrow Transplant 22:1851-60|
|Durai, Vivek; Murphy, Kenneth M (2016) Functions of Murine Dendritic Cells. Immunity 45:719-736|
|Brownson, Ross C; Dodson, Elizabeth A; Kerner, Jon F et al. (2016) Framing research for state policymakers who place a priority on cancer. Cancer Causes Control 27:1035-41|
|Chou, Chun; Verbaro, Daniel J; Tonc, Elena et al. (2016) The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses. Immunity 45:570-82|
|Niu, Haixia; Hadwiger, Gayla; Fujiwara, Hideji et al. (2016) Pathways of retinoid synthesis in mouse macrophages and bone marrow cells. J Leukoc Biol 99:797-810|
|Beeman, Scott C; Shui, Ying-Bo; Perez-Torres, Carlos J et al. (2016) O2 -sensitive MRI distinguishes brain tumor versus radiation necrosis in murine models. Magn Reson Med 75:2442-7|
|Mertins, Philipp; Mani, D R; Ruggles, Kelly V et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534:55-62|
|Murphy, Theresa L; Grajales-Reyes, Gary E; Wu, Xiaodi et al. (2016) Transcriptional Control of Dendritic Cell Development. Annu Rev Immunol 34:93-119|
Showing the most recent 10 out of 947 publications